Download Image
    
Share
  
Post
Pacritinib for COVID-19
1 study with 200 patients
Hospital Icon Control
Hospital Icon Pacritinib Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Pacritinib studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -28% Mortality -28% RCTs -28% Late -28% Favorspacritinib Favorscontrol
Dec 5
2022
 Cafardi et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.42918 Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19
28% higher mortality (p=0.63), 25% lower progression (p=0.38), and 17% worse improvement (p=0.53). RCT 200 hospitalized patients with severe COVID-19 showing no significant differences with pacritinib.